[시장보고서]소화성궤양 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 질환 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

소화성궤양 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 질환 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Disease Indication, By Distribution Channel, By Region and Competition, 2020-2030F

상품코드 : 1881481

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 188 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,715,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,207,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,938,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 소화성궤양 치료제 시장은 2024년 35억 4,000만 달러에서 2030년까지 43억 1,000만 달러로, CAGR 3.32%로 성장할 것으로 예측됩니다.

소화성궤양 치료제는 주로 헬리코박터 파일로리균 감염이나 비스테로이드성 항염증제(NSAIDs)의 장기 사용으로 인해 위, 소장, 식도의 점막에 발생하는 궤양을 치료하기 위해 처방되는 의약품입니다. 시장 확대는 전 세계 헬리코박터 파일로리균 감염 증가와 NSAIDs의 광범위한 사용이 주요 요인으로 작용하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	35억 4,000만 달러
시장 규모 : 2030년	43억 1,000만 달러
CAGR : 2025-2030년	3.32%
가장 빠르게 성장하는 부문	플로톤 펌프 억제제
최대 시장	북미

주요 시장 촉진요인

세계 소화성궤양 치료제 시장은 헬리코박터 파일로리균 감염의 지속적인 높은 발생률에 의해 크게 견인되고 있습니다. 이 박테리아는 소화성궤양 질환의 주요 원인균으로, 성공적인 근절과 치유를 위해서는 표적화된 항균 및 산분비 억제 요법이 필요합니다.

주요 시장 과제

세계 소화성궤양 치료제 시장의 지속적인 성장을 가로막는 가장 큰 장벽은 헬리코박터 파일로리 제균 요법에서 증가하고 있는 항생제 내성입니다. 이러한 문제는 기존 1차 치료제의 효과를 직접적으로 저해하고, 환자의 치료 결과를 최적화하지 못하는 결과를 초래하고 있습니다.

주요 시장 동향

세계 소화성궤양 치료제 시장에서는 산분비 억제 요법의 발전을 보여주는 칼륨 경쟁적 산분비 억제제(P-CABs)로의 전환이 눈에 띄게 진행되고 있습니다. P-CABs는 기존 양성자 펌프 억제제의 한계를 극복하고, 빠른 효과와 지속적인 산분비 억제라는 장점을 제공합니다.

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 제품 유형별(플로톤 펌프 억제제, 칼륨 경쟁형 산 분비 억제제(P-CAB), 제산제, H2 수용체 길항제, 항생제, 궤양 보호제)
- 질환별(위염, 위궤양, 십이지장궤양, 위식도역류질환(GERD))
- 유통 채널별(병원 약국, 소매 약국, E-Commerce)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 소화성궤양 치료제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 소화성궤양 치료제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 소화성궤양 치료제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 소화성궤양 치료제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 소화성궤양 치료제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 소화성궤양 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

Daewoong Pharmaceutical Co., Ltd
Takeda Pharmaceutical Co., Ltd.
Pfizer Inc.
AstraZeneca plc.
RedHill Biopharma Ltd.
Zydus Lifesciences Limited
ANI Pharmaceuticals, Inc.(Novitium Pharma LLC.)
Boehringer Ingelheim International GmbH
Eisai Co. Ltd.
Yuhan Corporation

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Peptic Ulcer Drugs Market will grow from USD 3.54 Billion in 2024 to USD 4.31 Billion by 2030 at a 3.32% CAGR. Peptic ulcer drugs comprise pharmaceutical agents formulated to treat open sores that develop on the lining of the stomach, small intestine, or esophagus, primarily resulting from *Helicobacter pylori* infection or prolonged use of nonsteroidal anti-inflammatory drugs. The market's expansion is fundamentally driven by the escalating global prevalence of *H. pylori* infections and the extensive use of NSAIDs.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.54 Billion
Market Size 2030	USD 4.31 Billion
CAGR 2025-2030	3.32%
Fastest Growing Segment	Proton Pump Inhibitors
Largest Market	North America

Key Market Drivers

The global peptic ulcer drugs market is significantly driven by the persistent high incidence of *Helicobacter pylori* infection. This bacterium is a primary etiological factor for peptic ulcer disease, necessitating targeted antimicrobial and acid-suppressing therapies for successful eradication and healing. The widespread nature of this infection ensures a continuous and substantial patient pool requiring diagnostic procedures and a comprehensive array of pharmaceutical interventions.

Key Market Challenges

A significant impediment to the sustained expansion of the global peptic ulcer drugs market is the escalating antibiotic resistance encountered in *Helicobacter pylori* eradication regimens. This challenge directly undermines the effectiveness of established first-line therapies, leading to suboptimal patient outcomes. When bacteria develop resistance to antibiotics, the standard treatment protocols become less efficacious, often necessitating longer treatment durations, the use of more complex drug combinations, or the administration of higher doses, all of which increase treatment burden and healthcare costs.

Key Market Trends

The global peptic ulcer drugs market is experiencing a significant shift towards Potassium-Competitive Acid Blockers (P-CABs), marking an advancement in acid suppression therapy. P-CABs offer benefits such as rapid onset and consistent acid suppression, addressing limitations of traditional proton pump inhibitors. Their integration into treatment protocols is expanding, especially for patients unresponsive to conventional therapies. According to the American Gastroenterological Association's Clinical Practice Update, published in January 2025, P-CABs are recommended in place of proton pump inhibitors for most patients with *Helicobacter pylori* and other conditions where initial therapies have failed.

Key Market Players

Daewoong Pharmaceutical Co., Ltd
Takeda Pharmaceutical Co., Ltd.
Pfizer Inc.
AstraZeneca plc.
RedHill Biopharma Ltd.
Zydus Lifesciences Limited
ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
Boehringer Ingelheim International GmbH
Eisai Co. Ltd.
Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptic Ulcer Drugs Market, By Product Type:

Proton Pump Inhibitors
Potassium-Competitive Acid Blocker (P-CAB)
Antacids
H2- Antagonist
Antibiotics
Ulcer Protective

Peptic Ulcer Drugs Market, By Disease Indication:

Gastitis
Gastric Ulcer
Duodenal Ulcer
Gastroesophageal Reflux Disease (GERD)

Peptic Ulcer Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Peptic Ulcer Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peptic Ulcer Drugs Market.

Available Customizations:

Global Peptic Ulcer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptic Ulcer Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective)
- 5.2.2. By Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD))
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Peptic Ulcer Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Disease Indication
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Peptic Ulcer Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Disease Indication
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Peptic Ulcer Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Disease Indication
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Peptic Ulcer Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Disease Indication
    - 6.3.3.2.3. By Distribution Channel

7. Europe Peptic Ulcer Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Disease Indication
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Peptic Ulcer Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Disease Indication
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Peptic Ulcer Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Disease Indication
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Peptic Ulcer Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Disease Indication
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Peptic Ulcer Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Disease Indication
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Peptic Ulcer Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Disease Indication
    - 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Peptic Ulcer Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Disease Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Peptic Ulcer Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Disease Indication
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Peptic Ulcer Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Disease Indication
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Peptic Ulcer Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Disease Indication
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Peptic Ulcer Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Disease Indication
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Peptic Ulcer Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Disease Indication
    - 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Peptic Ulcer Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Disease Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Peptic Ulcer Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Disease Indication
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. UAE Peptic Ulcer Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Disease Indication
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. South Africa Peptic Ulcer Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Disease Indication
    - 9.3.3.2.3. By Distribution Channel

10. South America Peptic Ulcer Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Disease Indication
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Peptic Ulcer Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Disease Indication
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Colombia Peptic Ulcer Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Disease Indication
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Argentina Peptic Ulcer Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Disease Indication
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Peptic Ulcer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Daewoong Pharmaceutical Co., Ltd
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Takeda Pharmaceutical Co., Ltd.
15.3. Pfizer Inc.
15.4. AstraZeneca plc.
15.5. RedHill Biopharma Ltd.
15.6. Zydus Lifesciences Limited
15.7. ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
15.8. Boehringer Ingelheim International GmbH
15.9. Eisai Co. Ltd.
15.10. Yuhan Corporation